NMR spectroscopic studies of intermediary metabolites of cyclophosphamide. A comprehensive kinetic analysis of the interconversion of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and the concomitant partitioning of aldophosphamide between irreversible fragmentation and reversible conjugation pathways
- PMID: 6708049
- DOI: 10.1021/jm00370a008
NMR spectroscopic studies of intermediary metabolites of cyclophosphamide. A comprehensive kinetic analysis of the interconversion of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and the concomitant partitioning of aldophosphamide between irreversible fragmentation and reversible conjugation pathways
Abstract
Multinuclear (31P, 13C, 2H, and 1H) Fourier-transform NMR spectroscopy, with and without isotopically enriched materials, was used to identify and quantify, as a function of time, the following intermediary (short-lived) metabolites of the anticancer prodrug cyclophosphamide (1, Scheme I): cis-4-hydroxycyclophosphamide (cis-2), its trans isomer (trans-2), aldophosphamide (3), and its aldehyde-hydrate (5). Under a standard set of reaction conditions (1 M 2,6-dimethylpyridine buffer, pH 7.4, 37 degrees C), the stereospecific deoxygenation of synthetic cis-4-hydroperoxycyclophosphamide (cis-12, 20 mM) with 4 equiv of sodium thiosulfate (Na2S2O3) afforded, after approximately 20 min, a "pseudoequilibrium" distribution of cis-2, 3, 5, and trans-2, i.e., the relative proportions of these reactants (57:4:9:30, respectively) remained constant during their continual disappearance. NMR absorption signals indicative of "iminophosphamide" (8) and enol 6 were not detected (less than 0.5-1% of the synthetic metabolite mixture). A computerized least-squares fitting procedure was applied to the individual 31P NMR derived time courses for conversion of cis-2, 3 plus 5 (i.e., "3"), and trans-2 into acrolein and phosphoramide mustard (4), the latter of which gave an expected array of thiosulfate S-alkylation products (e.g., 16) and other phosphorus-containing materials derived from secondary decomposition reactions. This kinetic analysis gave the individual forward and reverse rate constants for the apparent tautomerization processes, viz., cis-2 in equilibrium "3" in equilibrium trans-2, as well as the rate constant (k3) for the irreversible fragmentation of 3. The values of k3 at pH 6.3, 7.4, and 7.8 were equal to 0.030 +/- 0.004, 0.090 +/- 0.008, and 0.169 +/- 0.006 min-1, respectively. Replacement of the HC(O)CH2 moiety n 3 with HC(O)CD2 led to a primary kinetic isotope effect (kH/kD = 5.6 +/- 0.4) for k3. The apparent half-lives (tau 1/2) for cis-2, "3", and trans-2 under the standard reaction conditions, at "pseudoequilibrium" (constant ratio of cis-2/"3"/trans-2), were each equal to approximately 38 min, which is considerably shorter than the widely cited colorimetrically derived half-lives reported by earlier investigators. The values of tau 1/2 for cis-2, "3", and trans-2 were affected by pH in the same manner as that found for k3 but were relatively insensitive to the presence of either K+, Na+, Ca2+, or Mg2+. The presence of certain primary amines led to marked decreases in tau 1/2 and, in some cases, the formation of acyclic adducts of aldehyde 3.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
In situ preparation and fate of cis-4-hydroxycyclophosphamide and aldophosphamide: 1H and 31P NMR evidence for equilibration of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and its hydrate in aqueous solution.J Med Chem. 1984 Apr;27(4):490-4. doi: 10.1021/jm00370a010. J Med Chem. 1984. PMID: 6708051
-
Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis.Cancer Res. 1982 Mar;42(3):830-7. Cancer Res. 1982. PMID: 7059981
-
Half-life of oxazaphosphorines in biological fluids.Drug Metab Dispos. 1984 Sep-Oct;12(5):553-9. Drug Metab Dispos. 1984. PMID: 6149904
-
The chemistry of the metabolites of cyclophosphamide.Curr Pharm Des. 1999 Aug;5(8):627-43. Curr Pharm Des. 1999. PMID: 10469895 Review.
-
High-performance tandem mass spectrometry in metabolism studies.Xenobiotica. 1992 Sep-Oct;22(9-10):1207-19. doi: 10.3109/00498259209051874. Xenobiotica. 1992. PMID: 1441611 Review.
Cited by
-
Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus.Br J Clin Pharmacol. 2006 Oct;62(4):457-72. doi: 10.1111/j.1365-2125.2006.02690.x. Br J Clin Pharmacol. 2006. PMID: 16995867 Free PMC article.
-
Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients.Clin Pharmacol Ther. 2014 Jun;95(6):644-52. doi: 10.1038/clpt.2014.37. Epub 2014 Feb 18. Clin Pharmacol Ther. 2014. PMID: 24549002 Free PMC article.
-
Glutathione diminishes the anti-tumour activity of 4-hydroperoxycyclophosphamide by stabilising its spontaneous breakdown to alkylating metabolites.Br J Cancer. 1991 Jan;63(1):45-50. doi: 10.1038/bjc.1991.10. Br J Cancer. 1991. PMID: 1989664 Free PMC article.
-
Cyclophosphamides as hypoxia-activated diffusible cytotoxins: a theoretical study.J Comput Aided Mol Des. 2000 May;14(4):307-16. doi: 10.1023/a:1008128023564. J Comput Aided Mol Des. 2000. PMID: 10815768
-
Cellular glutathione as a protective agent against 4-hydroperoxycyclophosphamide cytotoxicity in K-562 cells.Cancer Chemother Pharmacol. 1990;26(6):397-402. doi: 10.1007/BF02994088. Cancer Chemother Pharmacol. 1990. PMID: 2225310
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Molecular Biology Databases
Miscellaneous